OBJECTIVE: The purpose of this study was to test the efficacy of clomipramine and fluoxetine, controlled by placebo, and compare their action in children and adolescents with anxiety disorders. METHOD:Thirty subjects (ages 7-17 years), who were diagnosed with generalized anxiety disorder and/or separation anxiety disorder and/or social phobia, were submitted to a 12 week double-blind, randomized, placebo-controlled trial of clomipramine and fluoxetine. The instruments included: the Schedule for Affective Disorders and Schizophrenia, the Multidimensional Anxiety Scale for Children, the Children's Depression Inventory, the Clinical Global Impressions, and the Children's Global Assessment Scale. RESULTS: All groups (clomipramine [n=9], fluoxetine [n=10], placebo [n=11]) showed a significant improvement after 12 weeks of treatment. There were significant differences between the fluoxetine and placebo groups in some ratings of anxiety severity and impairment. No significant differences were observed between clomipramine and placebo groups or between fluoxetine and clomipramine groups. CONCLUSIONS: Treatment with placebo showed an unusual high response rate. Clomipramine showed similar efficacy compared with fluoxetine, although it was not superior to placebo.
RCT Entities:
OBJECTIVE: The purpose of this study was to test the efficacy of clomipramine and fluoxetine, controlled by placebo, and compare their action in children and adolescents with anxiety disorders. METHOD: Thirty subjects (ages 7-17 years), who were diagnosed with generalized anxiety disorder and/or separation anxiety disorder and/or social phobia, were submitted to a 12 week double-blind, randomized, placebo-controlled trial of clomipramine and fluoxetine. The instruments included: the Schedule for Affective Disorders and Schizophrenia, the Multidimensional Anxiety Scale for Children, the Children's Depression Inventory, the Clinical Global Impressions, and the Children's Global Assessment Scale. RESULTS: All groups (clomipramine [n=9], fluoxetine [n=10], placebo [n=11]) showed a significant improvement after 12 weeks of treatment. There were significant differences between the fluoxetine and placebo groups in some ratings of anxiety severity and impairment. No significant differences were observed between clomipramine and placebo groups or between fluoxetine and clomipramine groups. CONCLUSIONS: Treatment with placebo showed an unusual high response rate. Clomipramine showed similar efficacy compared with fluoxetine, although it was not superior to placebo.
Authors: Arif Khan; Russell L Kolts; Mark H Rapaport; K Ranga Rama Krishnan; Amy E Brodhead; Walter A Browns Journal: Psychol Med Date: 2005-05 Impact factor: 7.723
Authors: Boris Birmaher; David A Axelson; Kelly Monk; Catherine Kalas; Duncan B Clark; Mary Ehmann; Jeffery Bridge; Jungeun Heo; David A Brent Journal: J Am Acad Child Adolesc Psychiatry Date: 2003-04 Impact factor: 8.829
Authors: Daniel A Geller; Joseph Biederman; S Evelyn Stewart; Benjamin Mullin; Andrés Martin; Thomas Spencer; Stephen V Faraone Journal: Am J Psychiatry Date: 2003-11 Impact factor: 18.112
Authors: Jeffrey R Strawn; Eric T Dobson; Jeffrey A Mills; Gary J Cornwall; Dara Sakolsky; Boris Birmaher; Scott N Compton; John Piacentini; James T McCracken; Golda S Ginsburg; Phillip C Kendall; John T Walkup; Anne Marie Albano; Moira A Rynn Journal: J Child Adolesc Psychopharmacol Date: 2017-04-06 Impact factor: 2.576
Authors: Cosima Locher; Helen Koechlin; Sean R Zion; Christoph Werner; Daniel S Pine; Irving Kirsch; Ronald C Kessler; Joe Kossowsky Journal: JAMA Psychiatry Date: 2017-10-01 Impact factor: 21.596